Pharmaceuticals, Biotechnology and Life Sciences
accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC)
Pfizer Inc. has announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
Novartis company has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel (etanercept) – a tumor necrosis factor alpha (TNF-alpha) inhibitor.
The Food and Drug Administration (FDA) is advising consumers not to purchase or use NATUREAL, a product promoted and sold for weight loss.
Bayer has announced that from September 30th to October first, Bayer CropScience is hosting over 175 industry professionals from over 15 different countries at its Horticulture Symposium in Puerto Vallarta, Mexico.
The National Institutes of Health has shared its second wave of grants to support the goals of the Brain Research through…
Pfizer Inc., in partnership with five leading breast cancer advocacy organizations, has announced the next chapter of the Breast Cancer: A Story Half Told initiative, launched in 2014 to identify public misperceptions and gaps in knowledge surrounding metastatic breast cancer (MBC), the most advanced form of breast cancer.
Pfizer Inc., the specialist in making contraceptive medicine, best known for making Viagra, has announced that its injectable contraceptive, Sayana Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection.
Eli Lilly and Company and Incyte Corporation have announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA).